OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Shaukat on the Benefit of Diverse Enrollment in Clinical Trials in CRC

August 31st 2022

Aasma Shaukat, MD, MPH, discusses the benefit of diverse enrollment in clinical trials in colorectal cancer.

Dr. Blay on Treatment Considerations in Soft Tissue Sarcomas

August 31st 2022

Jean-Yves Blay, MD, discusses treatment considerations in patients with soft tissue sarcomas.

Dr. LoRusso on the Benefit of Genetic Sequencing in Sarcomas

August 31st 2022

Patricia LoRusso, DO, discusses the benefit of genetic sequencing in soft tissue sarcomas.

Dr. Martin-Broto on the Current First-Line Treatment of Soft Tissue Sarcomas

August 31st 2022

Javier Martin-Broto, MD, PhD, discusses the current treatment landscape in the first-line setting for soft tissue sarcomas.

Women in Oncology: Prioritization and Passionate Legacies

August 30th 2022

Selina M. Luger, MD, FRCPC, Gail J. Roboz, MD, and Wendy Stock, MD, discuss how being female affected their careers and share the scientific achievements they most want to be remembered for in the leukemia field.

Dr. Al-Sawaf on the Benefit of Fixed-Duration Obinutuzumab/Venetoclax in CLL

August 29th 2022

Othman Al-Sawaf, MD, discusses the benefit of fixed-duration treatment with obinutuzumab plus venetoclax in chronic lymphocytic leukemia.

Dr. Barata on the Role of Maintenance Avelumab in Advanced Urothelial Cancer

August 29th 2022

Pedro C. Barata, MD, MSc, discusses the role of maintenance avelumab in advanced urothelial cancer.

Dr. Strickler on the Exploration of Frontline Tucatinib/Trastuzumab in HER2+ CRC

August 29th 2022

John H. Strickler, MD, discusses the investigation of frontline tucatinib plus trastuzumab in HER2-positive colorectal cancer.

Dr. Cohen on the Efficacy of Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma

August 28th 2022

Adam D. Cohen, MD, discusses the efficacy of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma.

Dr. Raje on the Utilization of bb21217 in Relapsed/ Refractory Multiple Myeloma

August 28th 2022

Noopur Raje, MD, discusses the utilization of bb21217 in patients with relapsed/refractory in multiple myeloma.

Dr. Richardson on Isatuximab Plus Pomalidomide/Dexamethasone in R/R Myeloma

August 27th 2022

Paul G. Richardson, MD, discusses the overall survival benefit displayed by isatuximab plus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.

Dr. Puertas‐Martinez on Carfilzomib and Dexamethasone plus Cyclophosphamide in Multiple Myeloma

August 27th 2022

Borja Puertas‐Martinez, MD, discusses the use of carfilzomib and dexamethasone with or without cyclophosphamide in patients with relapsed/refractory multiple myeloma.

Dr. Sklavenitis-Pistofidis on Single-Cell Dissection of Immune Cells in Smoldering Myeloma

August 26th 2022

Romanos Sklavenitis-Pistofidis, MD, discusses single-cell dissection of bone marrow and peripheral blood immune cells in smoldering multiple myeloma.

Dr. D'Agostino on Factors for Unsustained MRD Negativity in Multiple Myeloma

August 26th 2022

Mattia D'Agostino, MD, discusses factors that could lead to unsustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma who are transplant eligible.

Dr. Gadgeel on CNS Activity Achieved With Adagrasib in KRAS G12C+ NSCLC

August 25th 2022

Shirish M. Gadgeel, MD, discusses the efficacy of adagrasib in patients with KRAS G12C–mutated non–small cell lung cancer and central nervous system metastases.

Dr. Lunning on the Evolution of BTK Inhibitors in CLL

August 24th 2022

Matthew A. Lunning, DO, FACP, discusses the evolution of BTK inhibitors in chronic lymphocytic leukemia.

Dr. Ross on the Role of the Microbiome in CRC

August 24th 2022

Howard M. Ross, MD, discusses the role of the microbiome colorectal cancer.

Dr. Desai on the Ideal Patient for Bladder Preservation in Urothelial Cancer

August 24th 2022

Neil Desai, MD, discusses the ideal patient for bladder preservation in urothelial cancer.

Dr. Jonasch on the Target Population for Treatement with Belzutifan in RCC

August 24th 2022

Eric Jonasch, MD, discusses the best patient population when treating with belzutifan in clear cell renal cell carcinoma.

Dr. Desai on the Evolving Standard of Care in Urothelial Cancer

August 24th 2022

Neil Desai, MD, discusses the evolving standard of care in urothelial cancer.